Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is a major public health issue.The spike(S)protein mutation D614G became dominant in SARS-CoV-2 during...Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is a major public health issue.The spike(S)protein mutation D614G became dominant in SARS-CoV-2 during a global pandemic,which displayed increased infectivity.1 Entry of a virus into host cells is one of the most critical steps in the viral life cycle.Since blockade of the entry process is a promising therapeutic option for COVID-19,research attention has been focused on the discovery of viral entry inhibitors.Although SARS-CoV-2 entry inhibitor development is very attractive,no candidates have progressed into clinical trials yet.展开更多
基金This work was supported by the Key Laboratory of Infectious Diseases,CQMU,202001the Science and Technology Research Program of Chongqing Municipal Education Commission(KJQN202000418 to L-Y.H.)+1 种基金Emergency Project from the Science and Technology Commission of Chongqing(cstc2020jscx-fyzx0053,cstc2020jscx-dxwtB0050 to A-L.H.)the Emergency Project for Novel Coronavirus Pneumonia from the Chongqing Medical University(CQMUNCP0302 to K.W.).
文摘Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is a major public health issue.The spike(S)protein mutation D614G became dominant in SARS-CoV-2 during a global pandemic,which displayed increased infectivity.1 Entry of a virus into host cells is one of the most critical steps in the viral life cycle.Since blockade of the entry process is a promising therapeutic option for COVID-19,research attention has been focused on the discovery of viral entry inhibitors.Although SARS-CoV-2 entry inhibitor development is very attractive,no candidates have progressed into clinical trials yet.
